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Pseudomonas aeruginosa (Pa) and Burkholderia cepacia complex (Bcc) lung infections are
responsible for much of the mortality in cystic fibrosis (CF). However, little is known about the
ecological interactions between these two, often co-infecting, species. This study provides what
is believed to be the first report of the intra- and interspecies bacteriocin-like inhibition potential of
Pa and Bcc strains recovered from CF patients. A total of 66 strains were screened, and shown to
possess bacteriocin-like inhibitory activity (97% of Pa strains and 68% of Bcc strains showed
inhibitory activity), much of which acted across species boundaries. Further phenotypic and
molecular-based assays revealed that the source of this inhibition differs for the two species. In
Pa, much of the inhibitory activity is due to the well-known S and RF pyocins. In contrast, Bcc
inhibition is due to unknown mechanisms, although RF-like toxins were implicated in some strains.
These data suggest that bacteriocin-based inhibition may play a role in governing Pa and Bcc
interactions in the CF lung and may, therefore, offer a novel approach to mediating these often
fatal infections.
INTRODUCTION
Individuals with cystic fibrosis (CF) face a lifelong battle
with chronic bacterial lung infections. Pseudomonas
aeruginosa (Pa) is the predominant infectious agent in
the lungs of adult CF patients and most individuals are
infected shortly after birth (Cystic Fibrosis Foundation,
2007). Alginate-producing mucoid variants emerge over
the course of several years, and form dense bacterial
biofilms in the CF lung. Once established, eradication of
these infections is generally not possible (Govan & Deretic,
1996; Hentzer et al., 2001).
In the 1970s, members of the Burkholderia cepacia complex
(Bcc) of species were first identified in the airways of CF
patients (Govan & Deretic, 1996). Although few in number
(~3%), the clinical manifestations of these infections can
be severe (Cystic Fibrosis Foundation, 2007; Kalish et al.,
2006). Colonization may be asymptomatic, or result in
progressive decline in lung function. A smaller number of
infections result in ‘cepacia syndrome’, which is a fatal
pneumonia that results in death (Jones et al., 2004; Kalish
et al., 2006; Tablan et al., 1985). Given that CF patients are
initially infected with Pa, Bcc strains must either compete
with or act in synergy with established Pa biofilms (Al-
Bakri et al., 2004). How such interactions occur is
unknown. In fact, little is known about the process of
Bcc invasion and its outcomes. Do the strains from the two
species co-exist peacefully? Do Bcc strains out-compete and
displace pre-existing Pa strains? Few studies have sought to
address how these two bacterial species interact in the CF
lung (Al-Bakri et al., 2004; McKenney et al., 1995; Weaver
& Kolter, 2004).
One factor known to mediate bacterial interactions is the
production of potent toxins known as bacteriocins (Riley &
Gordon, 1999). Unlike traditional antibiotics, many bacter-
iocins have a relatively narrow killing range. They have been
implicated in intraspecific competition brought on by
limited nutrients (Riley & Wertz, 2002b). In some cases,
however, bacteriocins are also able to kill more broadly, and
they have been implicated as a primary mechanism for
mediating microbial diversity (Kerr et al., 2002).
Much is already known about pyocins, the bacteriocins
produced by Pseudomonas spp. In fact, more than 90% of
all Pa strains examined to date produce one or more of
three pyocin types: S, R and F (Fyfe et al., 1984). S pyocins
are high-molecular-mass proteins that resemble the well-
known colicins produced by Escherichia coli. They are
protease sensitive, and most kill by DNA degradation
Abbreviations: Bcc, Burkholderia cepacia complex; CF, cystic fibrosis;
Pa, Pseudomonas aeruginosa.
A supplementary table of primers is available with the online version of
this paper.
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2058 036848 G 2010 SGM Printed in Great Britain(Michel-Briand & Baysse, 2002). Four S pyocins (S1, S2, S3
and AP41) have been studied extensively (Duport et al.,
1995; Sano & Kageyama, 1981; Sano et al., 1990, 1993a, b)
(Fig. 1a). All S-pyocin operons share the presence of two
genes: the larger gene (toxin gene) provides the killing
activity, while the smaller (immunity gene) provides
immunity against killing by that pyocin. The toxin gene
comprises four domains: I produces receptor-binding
activity, which enables a pyocin to recognize a specific
target; II has an unknown function; III enables transloca-
tion of the toxin through the plasma membrane; and IV
produces the killing (DNase) activity (Michel-Briand &
Baysse, 2002).
The R and F pyocins, which resemble bacteriophage tails,
are resistant to nuclease and protease digestion, and they
kill by depolarizing the cell membrane. The genes encoding
these pyocins are found in a cluster (which is why they are
often referred to as RF pyocins), and they are located
between trpE (anthranilate synthase component I) and
trpG (anthranilate synthase component II) (Nakayama
et al., 2000; Shinomiya et al., 1983). Fig. 1(b) shows the
genetic organization of pyocin R2F2 genes. The open
reading frames (PRF3–PRF43) include regulatory, lysis,
and R and F pyocin genes. The lysis genes (PRF9, PRF24,
PRF25 and PRF26) are similar in sequence to the lysis
cassettes of P2 and lambda phages (Nakayama et al., 2000).
There are 16 R and F pyocin genes (PRF10–PRF23 and
PRF28–PRF43) (Nakayama et al., 2000). The encoded
proteins show high levels of sequence similarity to tail
genes of P2 and lambda phage (Nakayama et al., 2000). The
function of PRF5–PRF8 is unknown.
The S, R and F pyocins are controlled by the same ptrN and
ptrR regulatory genes (Fig. 1b) (Michel-Briand & Baysse,
2002; Nakayama et al., 2000). PtrN is a transcriptional
activator that is repressed by PtrR (Matsui et al., 1993).
Under DNA damage, RecA protein cleaves the PtrR
repressor protein, which leads to expression of ptrN.
PtrN binds to the regulatory sequence (P-box), thus
inducing transcription of pyocin genes (Matsui et al.,
1993).
Stress conditions, such as might be encountered in a CF
lung, may induce pyocin production. Microarray analysis
of Pa genomes has revealed that pyocin transcription is
upregulated by hydrogen peroxide and ciprofloxacin
(Brazas & Hancock, 2005; Chang et al., 2005). Waite &
Curtis (2009) investigated the effect of pyocins in mixed-
culture biofilms under aerobic and anaerobic conditions,
and revealed that sensitivity to pyocin increased under
anaerobic conditions. Further, Heo et al. (2007) revealed
that R pyocins provide a competitive advantage during
growth in planktonic conditions.
Far less is known about cepaciacins, which are the
bacteriocins produced by Burkholderia. Approximately
30% of Burkholderia cepacia (formerly Pseudomonas
cepacia) strains produce cepaciacins (Govan & Harris,
1985). The few characterized cepaciacins resemble R-type
pyocins, as they are resistant to trypsin digestion, and
appear phage-tail-like when viewed under the electron
microscope (Govan & Harris, 1985). Nothing further is
known about the abundance, diversity or molecular
biology of these toxins.
Fig. 1. Genetic organization of exemplar pyocin genes (adapted from Michel-Briand & Baysse, 2002). (a) S3 pyocin: P-box
refers to the binding site for PrtN (not shown); the toxin gene is divided into four domains: I–IV. (b) R2F2 pyocin. Arrows indicate
the direction of transcription.
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clinical strains of Pa and Bcc isolated from the CF lung
produce bacteriocins, and, if so, whether these play a role
in mediating intra- and interspecific bacterial interactions
in the CF lung. To this end, a collection of clinical Pa and
Bcc strains from CF patients was screened for bacteriocin
production and sensitivity. This collection consisted of
strains isolated as paired (one strain of Pa and one strain of
Bcc isolated from the same lung) or unpaired strains.
Phenotypic screens for bacteriocin production, coupled
with typing methods to identify individual bacteriocins,
revealed a diversity of inhibitory mechanisms. Further, the
patterns of within- and between-species inhibition sug-
gested a role for these toxins in mediating bacterial
interactions in the CF lung.
METHODS
Bacterial strains. The bacterial strains used in this study included a
total of 66 clinical strains of Pa (38 strains) and Bcc (28 strains)
obtained from the Children’s Hospital, Boston, MA, USA. The study
protocol was approved by the Committee on Human Research at the
Children’s Hospital, and written informed consent was obtained. The
clinical collection can be divided into two groups. The first was
composed of 14 Pa and seven Bcc paired isolates procured from seven
patients with CF. Each pair consisted of one Pa strain and one Bcc
strain isolated from the same CF patient. The second group was
composed of 24 Pa and 21 Bcc unpaired isolates, which were isolated
from 31 patients. The Bcc strains included four genomovars (1
Burkholderia vietnamiensis,1 2Burkholderia multivorans,1 1
Burkholderia dolosa and 4 Burkholderia cenocepacia). The reference
strain collection included bacteriocin-producer strains, which are Pa
strains known to produce the following pyocins: S1 and R4 (PML28),
AP41 and F3 (PAF41), S2, R and F (NIH18), and S2, R2 and F2
(PAO1) (Ito et al., 1970; Kuroda & Kageyama, 1981; Nakayama et al.,
2000; Sano et al., 1990; Seo & Galloway, 1990). The reference
collection also included indicator strains sensitive to various
combinations of pyocins: PML1516d (S1
SS2
SAP41
S), NIH3
(S1
SS2
SAP41
S), NIH3S1
R (S1
RS2
SAP41
S), NIH3S2
R (S1
SS2
RAP41
S),
NIH3AP41
R (S1
SS2
SAP41
R), 3295 (AP41
S), 3012 (AP41
SF3
S), 7NSK2
(S1
SS3
S), 7NSK2-fpvA (S1
SS3
R), PML14 (S1
SR1
SR2
SR3
SR4
SR5
S), 13s
(S1
SR1
SR2
SR3
SR4
SR5
S) and NIH5 (ATCC 25317) (F1
SF2
SF3
S) (de
Chial et al., 2003; Kageyama et al., 1979; Kuroda & Kageyama, 1981;
Sano & Kageyama, 1981; Sano et al., 1993a; Williams et al., 2008).
Four cloned S pyocins (S1, S2, S3 and AP41) were employed in this
bacteriocin identification scheme (Duport et al., 1995; Sano &
Kageyama, 1993; Sano et al., 1993b). There is no corresponding set of
Bcc reference strains.
Bacteriocin production and sensitivity screen. The patch assay
was used to identify bacteriocin-like inhibition, which involves
overnight growth in 10 ml Luria–Bertani (LB) broth at 37 uC, with
shaking at 250 r.p.m. A 6 ml volume of LB top agar (0.6%, w/v),
mixed with 3 ml mitomycin C (0.5 mgm l
21; Sigma) and 100 ml
indicator cells (10
8 cells), was plated as a lawn on an LB agar plate
(Pugsley & Oudega, 1987). The producer strain (~10
6 cells) was
spotted on the indicator overlay with a toothpick. Two spots per strain
were applied. After overnight incubation at 37 uC, the plates were
scored. If a strain produced an inhibition factor, such as a bacteriocin,
active against the lawn, a zone of inhibition appeared. The clinical
collectionwasscreenedinan all-by-allassay,i.e.eachstrainwasusedas
a potential inhibitor producer and indicator. The all-by-all patch assay
was done in duplicate. All positive results were tested a third time.
A one-tailed Mann–Whitney U test was used for non-parametric
comparison of inhibitory activities in order to identify significant
differences in inhibition frequencies (Zar, 1999).
Phenotypic bacteriocin identification. The clinical collection was
screened against the indicator strains using the patch assay. In
addition, a cell-free extract of each putative bacteriocin-producing
strain was subjected to trypsin digestion, filtration and freezing to
distinguish between protease-sensitive and phage-like bacteriocins
(Pugsley & Oudega, 1987; Riley et al., 2003). Cell-free extracts of
putative producer strains were digested with trypsin (5 mg ml
21) for
30 min at 25 uC (to inactivate protease-sensitive bacteriocins), frozen
at 270 uC (which tends to fracture phage-tail-type bacteriocins), and
filtered in a 100 kDa Microcon YM-100 centrifugal filter device
(Millipore) using centrifugation at 14000 r.p.m. for 12 min (which
tends to retain phage-tail-like bacteriocins). The treated cell-free
extracts were tested on the lawns of pyocin-sensitive reference and
clinical strains.
Molecular screening. Genomic DNA was isolated using a DNeasy
Tissue kit (Qiagen), and the Gram-negative protocol was applied to
2610
9 cells from an overnight culture. A standard PCR protocol was
used to screen genomes for the presence of all previously
characterized S-type pyocin genes (encoding S1, S2, S3 and AP41)
and their corresponding immunity genes (Duport et al., 1995; Sano &
Kageyama, 1993; Sano et al., 1993b). Multiple primer sets were
designed, based on existing pyocin sequences, to amplify different
regions of each S pyocin gene and the corresponding immunity genes
(see Supplementary Table S1, available with the online version of this
paper). Further, primer sets specific to the regulatory region (P-box)
of pyocins S1, S2 and AP41 were employed. Primers designed to
amplify the RF-type pyocins, targeting PRF10, PRF31 and PRF38
genes, were taken from the literature (Nakayama et al., 2000). NCBI
accession numbers of the sequenced pyocins, primer positions,
primer sequences, amplicon sizes and identities are given in Table S1.
RESULTS
Inhibitory activity in Pa and Bcc strains
A phenotypic screen for inhibitory activity and sensitivity
was conducted on a collection of 66 clinical strains of Pa
(38 strains) and Bcc (28 strains) isolated from CF patients.
The collection consisted of strains isolated as pairs, i.e. one
Pa strain and one Bcc strain isolated from the same patient
(taken from 7 patients, and resulting in 14 pairs; 14 Pa
strains paired with 7 Bcc strains), and unpaired strains (24
Pa and 21 Bcc strains). Bacteriocin production and
sensitivity was assayed in an all-by-all comparison, i.e.
each strain was used as a putative producer and sensitive
strain.
In this screen, Pa and Bcc strains showed different levels of
inhibitory activity. The majority of the Pa strains (97%)
were inhibitory (Table 1). Most (76%) inhibited both
species, resulting in similar levels of intra- versus
interspecific inhibition (92% versus 81%). Only 3% of
Pa strains showed no inhibitory activity.
The Bcc strains showed lower levels of overall inhibitory
activity (68%) (Table 1). The one-tailed Mann–Whitney U
test confirmed significantly higher levels of total inhibition
by Pa versus Bcc strains (P,0.0005). Similar to Pa, most
S. Bakkal and others
2060 Microbiology 156Bcc strains (43%) inhibited both species, again resulting in
similar levels of intra- versus interspecific inhibition (54%
versus 57%). A much larger fraction of Bcc strains (32%)
displayed no inhibitory activity.
The CF strain collection could be further divided into
strains isolated as paired strains or unpaired strains.
The paired and unpaired Pa strains showed similar
levels of total inhibitory activity (Table 1). All paired
and most unpaired (96%) isolates possessed inhibitory
activity. Most of the paired strains (86%) inhibited both
species, while the remainder inhibited either Bcc (7%) or
Pa (7%). Two of the paired Pa strains inhibited their Bcc
pair mates. The inhibitory unpaired Pa strains showed
similar patterns of inhibitory activity: 71% inhibited both
species, and the remainder inhibited either Bcc (4%) or
Pa (21%).
The paired Bcc strains showed inhibitory activity patterns
that were significantly different from their Pa pair mates
(Table 1). Only 43% of paired Bcc isolates possessed
inhibitory activity, at significantly lower levels than for
paired Pa isolates (0.025,P,0.05), and all of these strains
inhibited both species, but not their pair mates. The
unpaired Bcc isolates showed quite similar inhibitory
activity patterns compared with those of unpaired Pa
strains. Most of the unpaired Bcc strains were inhibitory
(76%), and most of these (43%) inhibited both species.
The remainder inhibited only Bcc (14%) or only Pa strains
(19%).
Inhibition haplotypes were determined for each producer
strain. The 37 Pa and 19 Bcc producers displayed 36 and
18 haplotypes, respectively (Fig. 2). Further, all Pa isolates
inhibited multiple Pa and Bcc strains; 12 Pa inhibited 1–
10 strains (11 inhibition haplotypes), 8 inhibited 11–20
strains (8 inhibition haplotypes), 11 inhibited 21–30
strains (11 inhibition haplotypes), and 3 inhibited 31–40
strains (3 inhibition haplotypes). Three of the paired Pa
isolates were able to inhibit most of the strains in the
collection (41–50 strains). The Bcc isolates had a more
limited inhibitory activity range. The majority (17 strains)
inhibited 1–10 strains (16 inhibition haplotypes). Two Bcc
strains were more broadly inhibitory, acting against 13 or
24 strains.
Bacteriocins of clinical Pa and Bcc strains are a
source of inhibitory activity
A series of phenotypic assays were employed to assess
whether the observed inhibitory activities were due to
bacteriocin or bacteriophage production. Cell-free extracts
of each producer strain were subjected to filtration (to
retain phage-like bacteriocins), protease digestion (to
digest protein moieties) and freezing (to fracture phage-
like bacteriocins). These assays revealed that 13% of the Pa
strains produced substances that appeared to be protease-
sensitive bacteriocins, 11% produced phage-like bacter-
iocins, and 63% produced both (Fig. 3). Finally, 11% of
the Pa strains could not be characterized because of loss of
inhibitory activity in the cell-free extract.
Surprisingly, all of the Bcc producer strains lost inhibitory
activity in their cell-free extracts. This result was further
explored by concentrating the extracts 20-fold. One strain
(4%) showed phage-like bacteriocin activity (Fig. 3), none
showed only protease-sensitive bacteriocin activity, and
11% showed both types of activity. One Bcc strain (4%)
Table 1. Inhibitory activity of Pa and Bcc strains from the CF lung
PI, paired isolates; UPI, unpaired isolates; NA, not applicable.
Inhibitory activity No. of Pa isolates (%) No. of Bcc isolates (%)
PI, n514 UPI, n524 Total, N538 PI, n57 UPI, n521 Total, N528
No inhibition 0 (0) 1 (4) 1 (3) 4 (57) 5 (24) 9 (32)
Inhibits only Pa 1 (7) 5 (21) 6 (16) 0 (0) 4 (19) 4 (14)
Inhibits only Bcc 1 (7) 1 (4) 2 (5) 0 (0) 3 (14) 3 (11)
Inhibits both Pa and Bcc 12 (86) 17 (71) 29 (76) 3 (43) 9 (43) 12 (43)
Total inhibition 14 (100) 23 (96) 37 (97) 3 (43) 16 (76) 19 (68)
Paired inhibition 2 (14) NA 2 (5) 0 (0) NA 0 (0)
Fig. 2. Inhibition haplotypes of clinical Pa and Bcc strains.
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activity was due to lytic activity of a bacteriophage. Finally,
50% could not be characterized because of complete loss of
inhibitory activity, even after 20-fold concentration of the
extract (Fig. 3).
Clinical strains have the potential to produce
multiple bacteriocins
A set of Pa reference strains was employed to identify the
source of some or all of the inhibition identified above.
These strains are either producers of, or are sensitive to,
specific S, R and F pyocins (de Chial et al., 2003; Ito et al.,
1970; Kageyama et al., 1979; Kuroda & Kageyama, 1981;
Nakayama et al., 2000; Sano et al., 1990; Seo & Galloway,
1990; Williams et al., 2008). To permit an even finer degree
of bacteriocin identification, cloned pyocins (S1, S2, S3 and
AP41) (Duport et al., 1995; Sano & Kageyama, 1981; Sano
et al., 1993b) were employed as references. There are no
corresponding reference strains for Bcc bacteriocins.
All strains were assayed for bacteriocin-like inhibitory
activity against the Pa reference collection. The bacteriocin
phenotypes predicted from these inhibition haplotypes are
given in Table 2. Among the 37 Pa producer strains, 76%
inhibited one or more of the reference strains. Strains
predicted to possess the most bacteriocins (Pa I: S1, S2, S3,
AP41, R2, R4, F2, F3; and Pa II: S1, S2, AP41, R2, R4, F2,
F3) were the most common phenotypes encountered in the
clinical Pa strains. These two phenotypes inhibited an
average of 31 and 23 strains, respectively. Pa II strains,
possessing all but the S3 phenotype (PaIIS3
2), showed a
42% decrease in Bcc inhibition in comparison with Pa I.
The Pa III (S1, R2, R4, F2) phenotype was found in only
one strain; however, it inhibited the greatest number of
clinical strains, an average of 44 strains. Pa strains with the
Pa IV (S1, R2, R4, F2, F3) and Pa V (S1, S3, AP41, R2, R4,
F2, F3) phenotypes inhibited the least number of clinical
strains, an average of 6.5 and 9, respectively. Strains with
the Pa VI (S1, S2, AP41) phenotype inhibited a mean of 17
clinical strains. Nine Pa producer strains (Pa VII) did not
inhibit any of the reference strains, and had the lowest level
of inhibition, with an average of 2.4 clinical strains
inhibited. Among the 19 Bcc producer strains, only three
(16%) inhibited any of the Pa reference strains. These
three strains possessed the Bcc I (S1, S2, AP41, F3), Bcc II
(F3) and Bcc III (R2, F2) phenotypes (Table 2). Sixteen Bcc
producer strains (Bcc IV) did not inhibit any of the
reference strains, and they inhibited an average of 5.8
clinical strains.
Clinical strains show sensitivity to multiple
bacteriocins
The clinical strains were exposed to cloned S pyocins
(Duport et al., 1995; Sano & Kageyama, 1981; Sano et al.,
Fig. 3. Inhibition types produced by clinical Pa and Bcc strains.
Table 2. Bacteriocin phenotypes of clinical Pa and Bcc strains
Producer
species
Phenotype
designation
Bacteriocin phenotype* No. of
strains
Mean no. of Pa
strains inhibited
Mean no. of Bcc
strains inhibited
Total no. of
strains inhibited
Pa Pa I S1, S2, S3, AP41, R2, R4, F2, F3 10 19 12 31
Pa II S1, S2, AP41, R2, R4, F2, F3 12 16 7 23
Pa III S1, R2, R4, F2 1 18 26 44
Pa IV S1, R2, R4, F2, F3 2 5.5 1 6.5
Pa V S1, S3, AP41, R2, R4, F2, F3 1 6 3 9
Pa VI S1, S2, AP41 2 8.5 8.5 17
Pa VII – 9 1.8 0.6 2.4
Bcc Bcc I S1, S2, AP41, F3 1 6 4 10
Bcc II F3 1 4 2 6
Bcc III R2, F2 1 1 2 3
Bcc IV – 16 2.8 3 5.8
*S-type pyocins: S1, S2, S3 and AP41; RF-type pyocins: R2, R4, F2 and F3.
S. Bakkal and others
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cent of these strains were sensitive to a single pyocin,
and 38% were sensitive to multiple pyocins. Finally, none
of the Bcc strains were sensitive to the cloned S pyocins
(Table 3).
Source of the intra- and interspecific inhibitory
activity of clinical strains
Based on inhibition haplotypes, 28 Pa strains were
predicted to produce combinations of S- and RF-type
pyocins, which kill within and between species (Fig. 4).
Two strains inhibited intraspecifically with S pyocins, 24
with RF-type pyocins, and 25 with S and/or RF pyocins.
Twenty-five strains acted interspecifically, all with RF-type
pyocins. Finally, 14 produced novel bacteriocins that acted
intraspecifically (50%) or interspecifically (50%).
In contrast, the majority of Bcc strains produced novel
bacteriocin-like activity (Fig. 4). Three strains produced
RF-like factors, and 12 produced novel bacteriocins, all of
which acted intraspecifically. Further, three produced RF-
like pyocins, one produced S- and/or RF-like pyocins, and
the remainder (13) produced novel inhibitors that
inhibited interspecifically (Fig. 4).
Molecular screening: clinical Pa strains possess
multiple pyocin genes
PCR primers specific to S-type (S1, S2, S3 and AP41)
(Duport et al., 1995; Sano & Kageyama, 1981; Sano et al.,
1993b) and RF-type (PRF10, PRF31 and PRF38) pyocin
genes were employed to screen for the presence of known
pyocin-encoding genes (Supplementary Table S1). All Pa
strains were amplification positive for one or more of the
pyocin genes (Fig. 5). Ninety-five per cent of the strains
possessed one or more S-pyocin genes: 71% amplified
from the S1 gene, 71% from the S2 gene, 42% from the S3
gene, and 63% from the AP41 gene. A further 16%
amplified from the pyocin AP41 immunity gene, but not
the corresponding toxin gene. Ninety-five per cent of the
strains were amplification positive for one or more RF-
pyocin genes; 68% for PRF10, 45% for PRF31, and 24%
for PRF38 (Fig. 5). Finally, none of the Bcc strains were
amplification positive for any of the pyocin genes (data not
shown).
DISCUSSION
Individuals with CF face a lifelong battle with chronic
bacterial lung infections (Govan & Deretic, 1996). Pa is the
most prevalent species in the CF lung, and is associated
with high mortality (Cystic Fibrosis Foundation, 2007;
Emerson et al., 2002). CF patients are first colonized with
non-mucoid Pa in childhood, which is replaced by mucoid
variants in adulthood (Gibson et al., 2003). Mucoid Pa
form biofilms that are virtually impossible to eradicate,
even with aggressive antibiotic therapy (Hentzer et al.,
2001). Secondary bacterial infections, such as with B.
cepacia, although less common, are of particular concern
because they are often associated with faster decline in lung
function, and may result in cepacia syndrome, which is a
rapidly progressing and fatal pneumonia (Huang et al.,
2001; Lambiase et al., 2006). What is remarkable about
these secondary infections is that they require a strain that
is able to compete with, and perhaps even displace, the
established Pseudomonas strain (Lambiase et al., 2006;
Ledson et al., 1998, 2002; McManus et al., 2004). Further,
Table 3. S-pyocin sensitivity of clinical Pa and Bcc strains
Cloned S pyocins were used for these assays. None of the 28 Bcc
strains were sensitive to the cloned S pyocins.
Pyocin-sensitivity phenotype* No. of sensitive Pa strains
(n538)
S1 3
S2 0
S3 13
AP41 5
S1, S2 6
S1, S3 0
S1, AP41 1
S2, S3 0
S2, AP41 0
S3, AP41 3
S1, S2, AP41 1
S1, S3, AP41 2
S2, S3, AP41 0
S1, S2, S3, AP41 0
Total sensitivity 34 (89%)
*Phenotypes are according to sensitivity to S-pyocin producing
clones; e.g. S1: only S1 sensitivity; S1, S2: S1 and S2 sensitivity.
Fig. 4. Source of the intra- and interspecific inhibitory activity of
clinical Pa and Bcc strains.
Bacteriocins of clinical CF strains
http://mic.sgmjournals.org 2063the time interval between exposure and invasion may be as
short as days to weeks (Ledson et al., 1998; Tablan et al.,
1985; Whiteford et al., 1995). This ability of Bcc strains to
compete with, or even displace, the resident Pa strains
stands in sharp contrast with our seeming inability to
significantly impact long-standing Pseudomonas lung
infections with even the most aggressive use of broad-
spectrum antibiotics.
Bacteriocins, narrow-spectrum antimicrobials, are recog-
nized as one of the most common mechanisms by which
bacteria mediate population- and community-level inter-
actions (Kerr et al., 2002; Riley & Gordon, 1999; Riley &
Wertz, 2002b). It is already well known that Pa is one of the
most prolific bacteriocin producers. Indeed, studies indicate
that nearly all clinical, and only slightly fewer environmental
(~70%) Pa strains produce typable pyocins (Bouhaddioui
et al., 2002; Farmer & Herman, 1969; Jones et al., 1974;
Zabransky & Day, 1969). Typing of a much smaller number
of B. cepacia (previously known as P. cepacia) strains from
clinical sources has revealed far fewer producers (30%) of
putative bacteriocin-like toxins (labelled cepaciacins)
(Govan & Harris, 1985). What little we know about
cepaciacins suggests that some may be similar to the
phage-tail-like R pyocins (Govan & Harris, 1985).
In an attempt to understand how Pa and Bcc strains
interact in the CF lung, isolates of both species were
surveyed for the production of bacteriocins. Not surpris-
ingly, both species were found to be prolific producers of
bacteriocin-like toxins, with 97% of Pa strains and 68% of
Bcc strains capable of inhibition (Table 1). For Pa, most of
the inhibitory activity detected (76%) was due to S and RF
pyocins (Table 2). In contrast, for Bcc, most of the
inhibition could not be characterized (Table 2), and only a
small fraction (16%) was attributable to bacteriocin-like
proteins (Table 2).
More surprisingly, the levels of between-species inhibition
were high: 81% of the Pa producer strains and 57% of the
Bcc producers inhibited the other species (Table 1).
Previous studies of Gram-negative bacteriocins have
described bacteriocins as narrow-spectrum toxins, referring
to the observation that they are active against members of
the same species, and generally display restricted levels of
inhibition outside of the producing species (Riley & Wertz,
2002a, b). For example, a sample of 122 closely related
Klebsiella species possess only 20% interspecific inhibitory
activity (Riley et al., 2003).
The high levels of interspecific inhibition detected for Pa
and Bcc may reflect the competitive interactions that occur
between these species in the CF lung. Prior studies have
suggested that these two species actively inhibit each
other’s growth. McKenney et al. (1995) revealed that the
addition of cell-free Pa exo-products to the growth
medium used to cultivate Bcc enhances the production
of siderophores, lipases and proteases. Further, Weaver &
Kolter (2004) examined the effect of cell-free extracts of
Bcc on Pa gene expression, and revealed that most of the
upregulated genes of Pa are normally induced under iron-
limited conditions. The authors concluded that iron-
limited conditions might be created in these pairwise
growth conditions due to the iron chelator ornibactin
produced by Bcc. Indeed, iron siderophores and S pyocins
(S2, S3) share the same receptors (type I and II
ferripyoverdines, respectively) (Denayer et al., 2007).
Thus, S pyocins are better absorbed by sensitive strains
under iron-limited conditions (Ohkawa et al., 1980). Given
these facts, Bcc colonization in the CF lung may induce
intraspecific Pa inhibitory activity. Clearly, the effect of
iron on the interspecific inhibitory activity of pyocins and
cepaciacins warrants further investigation. For these
purposes, identification of cepaciacins and the correspond-
ing cell surface receptors is required.
The majority of Pa interspecific inhibitory activity was due
to RF-type pyocins (Fig. 4). In fact, R pyocins inhibit a
variety of Gram-negative bacteria (Blackwell et al., 1979;
Filiatrault et al., 2001). This study provides what is thought
Fig. 5. Pyocin gene distribution in the gen-
omes of clinical Pa strains.
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pyocins in inhibition of clinical Bcc strains. The remainder
of the Pa interspecific inhibitory activity was due to novel
virulence factors. The majority of Bcc interspecific
inhibitory activity was due to novel factors (Fig. 4), which
requires further investigation.
Another intriguing observation reported here is that most
isolates of Pa from the CF lung produced multiple
bacteriocins (Table 2, Fig. 5). In fact, the most frequently
encountered bacteriocin types (Pa I–II) included essentially
all characterized S and RF pyocins. The observation of such
high levels of Pa bacteriocin diversity is good news for
those interested in the potential use of bacteriocins as
narrow-spectrum antimicrobials. Although the bacterio-
cin-like production patterns were complex, they offered a
wide range of inhibition specificities.
Given the lack of effective antibiotic therapies for adult
patients with CF, it is intriguing that the strains tested here
were inhibited by a diversity of Pa and Bcc bacteriocins
(real and putative). Bacteriocins may be an effective
alternative for mediating some of these long-standing
infections. One requirement would be the production of
bacteriocin-sensitivity profiles to permit identification of
the appropriate therapeutic bacteriocins. Of course, such
treatment will select for bacteriocin resistance (e.g. protease
sensitivity, LPS receptor modification) (Loutet et al., 2006).
However, given the plethora of potential bacteriocins,
cocktails of toxins could be created that would result in far
lower rates of resistance evolution (M. A. Riley, unpub-
lished observations). Bacteriocins are now frequently being
considered for such therapeutic use (Gillor et al., 2005).
For example, they are employed as antibiotics for treatment
of mastitis in dairy cows (Diez-Gonzalez, 2007), and to
inhibit growth of pathogenic E. coli in newborn piglets and
foals (Gillor et al., 2005).
The most striking difference between the inhibitory
patterns of the Pa and Bcc strains involved their breadth
of activity. Almost all Pa isolates were able to inhibit a wide
range of Pa and Bcc strains (Fig. 2). In contrast, Bcc strains,
on average, inhibited a much more limited number of
strains. Further, the Bcc inhibitory substances appeared to
be phenotypically unique. For example, standard bacter-
iocin assays are highly successful when applied to most
species of Gram-negative bacteria (Pugsley & Oudega,
1987; Riley et al., 2003), yet these methods were far less
effective when applied to Bcc strains. Most intriguing was
the complete loss of all inhibitory activity in Bcc cell-free
extracts. Even with 20-fold concentrations, it was not
possible to recover inhibitory activity, which had been
clearly and repeatedly observed on plate-based screens. In
fact, the most successful protocols for obtaining Bcc
inhibition involved concomitant growth of both the
producer and sensitive strains on a solid surface. Perhaps
inhibition production requires severely restricted resources
and/or high levels of competition. An alternative explana-
tion could be the presence of unstable phage particles in
lysates from producer strains (Summer et al., 2004).
Although we were unable to propagate bacteriophage
activity, one Bcc strain was clearly shown to inhibit via
phage (Fig. 3). Recent studies on the bacteriophages of Bcc
have revealed that bacteriophages are able to inhibit
different Bcc genomovars. However, these phages have a
relatively limited ability to inhibit Pa strains (Langley et al.,
2003; Seed & Dennis, 2005). Clearly, this intriguing loss of
inhibitory activity for the majority of Bcc producers
requires further investigation.
Pa strains are usually the persistent resident bacterial
species in the adult CF lung. A recent study revealed a clear
example of how R pyocins may play a role in mediating
intraspecific competition and succession of Pa strains (Heo
et al., 2007). Further, pyocin production has been shown to
impact intraspecific interactions in mixed biofilms (Waite
& Curtis, 2009). It is rare for a Bcc strain to be able to
invade these established populations. In the relatively
infrequent cases of co-existence (i.e. the paired strains in
this study), the Pa and Bcc strains are usually unable to
inhibit each other. Only two Pa strains (via RF pyocins)
and none of the Bcc strains were able to inhibit their pair
mates (Table 1, Fig. 4). This observation may simply reflect
the outcome of prior competition: if one or the other
was able to inhibit the invader or resident strain, they
would not be found to coexist. Clearly most unpaired Pa
and Bcc strains were able to inhibit each other (75% versus
62%, respectively), even while the pair mates could not
(Table 1).
Future efforts will focus on two significant features of
bacteriocin biology revealed by this study. First, it is
surprising that there have been no molecular investigations
of cepaciacins. Given the importance of Bcc in human
disease, the presence of these potent toxins should
have generated prior interest. In contrast, numerous
studies have focused on the characterization of pyocins.
Preliminary studies designed to provide a molecular
characterization of cepaciacins identified here caution us
that this may not be a simple exercise. To date, our efforts
have not resulted in a single cloned cepaciacin, or even a
bacteriocin-like inhibitory function, from these Bcc strains.
Second, the suggestion that bacteriocin-like inhibition may
play a role in mediating strain dynamics in the CF lung
serves as inspiration for future studies designed to
characterize the potential of these narrow-spectrum anti-
microbials to serve as future CF therapeutics. Clearly, such
toxins are able to mediate interspecific interactions of Pa
and Bcc. Whether we can employ these toxins for our own
purposes in a clinical setting remains to be seen.
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